What is HC Wainwright’s Estimate for InflaRx Q3 Earnings?

InflaRx N.V. (NASDAQ:IFRX) – Analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for InflaRx in a research note issued to investors on Tuesday, September 2nd. HC Wainwright analyst M. Keller forecasts that the company will post earnings per share of ($0.13) for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for InflaRx’s Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.71) EPS and FY2028 earnings at ($0.72) EPS.

A number of other analysts have also commented on the company. Oppenheimer lowered their price objective on InflaRx from $6.00 to $3.00 and set an “outperform” rating for the company in a research report on Thursday, May 29th. Raymond James Financial lowered InflaRx from a “strong-buy” rating to an “outperform” rating and set a $2.00 price objective for the company. in a research report on Thursday, May 29th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $6.20.

InflaRx Stock Down 9.2%

Shares of IFRX stock opened at $1.57 on Thursday. The stock has a 50-day moving average price of $0.95 and a 200 day moving average price of $1.14. The firm has a market cap of $105.39 million, a price-to-earnings ratio of -1.96 and a beta of 1.43. InflaRx has a 12 month low of $0.71 and a 12 month high of $2.82.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.24). The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.02 million.

Hedge Funds Weigh In On InflaRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. bought a new position in InflaRx during the second quarter worth about $262,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in InflaRx by 158.3% during the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock worth $118,000 after buying an additional 91,927 shares during the last quarter. Concurrent Investment Advisors LLC bought a new position in InflaRx during the second quarter worth about $65,000. Woodline Partners LP bought a new position in InflaRx during the first quarter worth about $766,000. Finally, 683 Capital Management LLC lifted its holdings in shares of InflaRx by 26.8% during the 1st quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock valued at $2,678,000 after purchasing an additional 555,000 shares in the last quarter. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.